NCT01937559

Topical Tranexamic Acid (TXA) in Joint Arthroplasty

Topical Application of Tranexamic Acid in Joint Arthroplasty

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 188 (actual)
• Sponsor: The Hawkins Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hypothesize that topical application of TXA prior to closure reduces postoperative bleeding as measured by absolute changes in postoperative hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic acid may reduce the need for transfusions, the rates of hematomas, infections, and length of hospital stay.

Conditions

• Osteoarthritis
• Hip Arthropathy
• Shoulder Arthropathy

Interventions

Type	Name	Description
BIOLOGICAL	Tranexamic acid (TXA)	1.5g of TXA in 100ml normal saline solution
DRUG	Normal saline

Timeline

• Start date: 2013-04-01
• Primary completion: 2018-06-01
• Completion: 2018-11-01
• First posted: 2013-09-09
• Last updated: 2020-05-05
• Results posted: 2020-05-05

Locations

1 site across 1 country: United States